<Disease><Name>CANAVAN DISEASE (ASPA)</Name><Synonym>AMINOACYLASE 2 DEFICIENCY; CANAVAN-VAN BOGAERT-BERTRAND DISEASE</Synonym><OMIM><Number>271900</Number><URL>http://omim.org/entry/271900</URL></OMIM><Orphanet><Number>141</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=141</URL></Orphanet><Protein><Number>aspartoacylase</Number><URL>http://www.uniprot.org/uniprot/P45381</URL></Protein><ExPASy><Number>3.5.1.15</Number><URL>http://enzyme.expasy.org/EC/3.5.1.15</URL></ExPASy><Gene>17p13.2</Gene><ICD>E75.2</ICD><Summary>rare (1:200000, 1:6000 - 1:14000 among the Ashkenazi) ;autosomal recessive ;mutation in the gene encoding aspartoacylase (ASPA) ;Juvenile onset: cerebellar signs, optic atrophy, visual loss. Janson CG published 2 cases who presented at age 50 and 19 months with developmental delay but without macrocephaly, hypotonia, spasticity, or seizures.</Summary><Symptoms><symtomp><id>2363</id><symptom>basal ganglia, changes, lesions, calcifications (MRI, CT)</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2211</id><symptom>blindness, visual loss, visual impairment</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>2226</id><symptom>cerebral atrophy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1983</id><symptom>constipation</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>2117</id><symptom>CT, brain, abnormalities [-] / CT, kraniell, abnormal </symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>3819</id><symptom>developmental delay</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2564</id><symptom>DNA / deoxyribonucleic acid</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>2164</id><symptom>dysarthria</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>2227</id><symptom>dysmorphism / dysmorphic features</symptom><category>HEAD</category></symtomp><symtomp><id>2423</id><symptom>early death</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2105</id><symptom>encephalopathy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3709</id><symptom>epilepsy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1969</id><symptom>extrapyramidal signs</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1979</id><symptom>feeding difficulties, poor feeding</symptom><category>GASTROINTESTINAL SYSTEM | GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>1713</id><symptom>fever, severe or recurrent</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2433</id><symptom>hearing defect, deafness</symptom><category>EARS | NERVOUS SYSTEM</category></symtomp><symtomp><id>1896</id><symptom>hypertonia, spasticity</symptom><category>MUSCLES</category></symtomp><symtomp><id>1897</id><symptom>hypotonia</symptom><category>MUSCLES | NERVOUS SYSTEM</category></symtomp><symtomp><id>3826</id><symptom>intellectual disability/intellectual developmental disorder</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1951</id><symptom>irritability</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2304</id><symptom>joint stiffness</symptom><category>SKELETAL DEFECT</category></symtomp><symtomp><id>1953</id><symptom>lethargy, drowsiness, apathy</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>3843</id><symptom>leukodystrophy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3993</id><symptom>loss of early milestones / loss of milestones</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1887</id><symptom>macrocephaly (large calvaria, &gt;2 SD for age)</symptom><category>HEAD</category></symtomp><symtomp><id>2424</id><symptom>mental retardation</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1886</id><symptom>microcephaly (&lt;2 SD for age)</symptom><category>HEAD</category></symtomp><symtomp><id>1941</id><symptom>motor retardation / motor developmental delay</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2213</id><symptom>MRI, brain, abnormalities [-]</symptom><category>LABORATORY FINDINGS | NERVOUS SYSTEM</category></symtomp><symtomp><id>2479</id><symptom>MRS, brain, abnormalities / Magnetic resonance spectroscopy (MRS)</symptom><category>LABORATORY FINDINGS | LABORATORY FINDINGS</category></symtomp><symtomp><id>2418</id><symptom>myelination, incomplete, hypomyelination</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1900</id><symptom>myoclonus</symptom><category>MUSCLES | NERVOUS SYSTEM</category></symtomp><symtomp><id>1917</id><symptom>neurological deterioration / neurologic deterioration</symptom><category>GENERAL TOPICS | NERVOUS SYSTEM</category></symtomp><symtomp><id>1723</id><symptom>nystagmus</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>2507</id><symptom>onset, childhood / childhood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2505</id><symptom>onset, infancy / infancy</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2504</id><symptom>onset, neonatal / neonatal</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2298</id><symptom>opisthotonus</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1739</id><symptom>optic atrophy</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>3322</id><symptom>poor or absent head control</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3680</id><symptom>psychomotor retardation</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1943</id><symptom>seizures</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>1874</id><symptom>speech development, delayed, abnormal</symptom><category>GENERAL TOPICS | NERVOUS SYSTEM</category></symtomp><symtomp><id>2263</id><symptom>strokelike episodes</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2142</id><symptom>swallowing difficulties</symptom><category>GASTROINTESTINAL SYSTEM | GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>1934</id><symptom>sweating</symptom><category>GENERAL TOPICS | SKIN</category></symtomp><symtomp><id>1944</id><symptom>tremor or twitching</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1980</id><symptom>vomiting</symptom><category>GASTROINTESTINAL SYSTEM | GENERAL TOPICS</category></symtomp><symtomp><id>3902</id><symptom>white matter changes, abnormalities</symptom><category>NERVOUS SYSTEM</category></symtomp></Symptoms><Metabolites><metabolite><id>2070</id><name>N-Acetylaspartic acid</name><specimen>urine</specimen><value>increased</value><min>6.00</min><max>36.00</max><unit>mmol/mol creatinine</unit><age>ALL</age><method>GCMS</method><comment /></metabolite><metabolite><id>1603</id><name>Choline</name><specimen>urine</specimen><value>decreased</value><min>1.40</min><max>6.10</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1606</id><name>Citric acid</name><specimen>urine</specimen><value>decreased</value><min>49.00</min><max>600.00</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1666</id><name>N-Acetylaspartic acid</name><specimen>urine</specimen><value>increased</value><min>1.30</min><max>7.00</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1706</id><name>Succinic acid</name><specimen>urine</specimen><value>increased</value><min>9.00</min><max>360.00</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1740</id><name>Choline</name><specimen>urine</specimen><value>decreased</value><min>0.00</min><max>94.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1776</id><name>N-Acetylaspartic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>48.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1806</id><name>Citric acid</name><specimen>urine</specimen><value>increased</value><min>46.00</min><max>1400.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>1817</id><name>Succinic acid</name><specimen>urine</specimen><value>increased</value><min>9.00</min><max>360.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>2071</id><name>N-Acetylaspartic acid</name><specimen>cerebrospinal fluid</specimen><value>increased</value><min>0.25</min><max>2.80</max><unit>&#956;mol/l</unit><age>ALL</age><method>GCMS</method><comment /></metabolite><metabolite><id>978</id><name>Aspartoacylase</name><specimen>fibroblasts</specimen><value>decreased</value><min>    </min><max>100.00</max><unit>% activity</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>1080</id><name>Cholestanol</name><specimen>plasma</specimen><value>decreased</value><min>    </min><max>    </max><unit>no data</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>450</id><name>Citric acid</name><specimen>urine</specimen><value>decreased</value><min>59.00</min><max>652.00</max><unit>mmol/mol creatinine</unit><age>adolescence</age><method /><comment /></metabolite><metabolite><id>587</id><name>Citric acid</name><specimen>urine</specimen><value>decreased</value><min>25.00</min><max>3168.00</max><unit>mmol/mol creatinine</unit><age>infancy</age><method /><comment /></metabolite><metabolite><id>588</id><name>Citric acid</name><specimen>urine</specimen><value>decreased</value><min>75.00</min><max>667.00</max><unit>mmol/mol creatinine</unit><age>childhood 4-6y</age><method /><comment /></metabolite><metabolite><id>589</id><name>Citric acid</name><specimen>urine</specimen><value>decreased</value><min>33.00</min><max>445.00</max><unit>mmol/mol creatinine</unit><age>childhood 6-12y</age><method /><comment /></metabolite><metabolite><id>1436</id><name>Citric acid</name><specimen>urine</specimen><value>decreased</value><min>490.00</min><max>1076.00</max><unit>mmol/mol creatinine</unit><age>newborn 1-7d</age><method /><comment /></metabolite><metabolite><id>384</id><name>Citric acid</name><specimen>cerebrospinal fluid</specimen><value>increased</value><min>90.00</min><max>590.00</max><unit>&#956;mol/l</unit><age>child</age><method /><comment /></metabolite><metabolite><id>385</id><name>Citric acid</name><specimen>plasma</specimen><value>increased</value><min>30.00</min><max>400.00</max><unit>&#181;mol/l</unit><age>child</age><method /><comment /></metabolite><metabolite><id>586</id><name>Citric acid</name><specimen>urine</specimen><value>increased</value><min>89.50</min><max>1647.70</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>714</id><name>Citric acid</name><specimen>cerebrospinal fluid</specimen><value>increased</value><min>64.00</min><max>167.00</max><unit>&#956;mol/l</unit><age>infant</age><method /><comment /></metabolite><metabolite><id>719</id><name>Citric acid</name><specimen>cerebrospinal fluid</specimen><value>increased</value><min>0.00</min><max>100.00</max><unit>&#956;mol/l</unit><age>child</age><method /><comment /></metabolite><metabolite><id>576</id><name>N-Acetylaspartic acid</name><specimen>urine</specimen><value>increased</value><min>5.00</min><max>66.00</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>577</id><name>N-Acetylaspartic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>56.00</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method /><comment /></metabolite><metabolite><id>578</id><name>N-Acetylaspartic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>39.00</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method /><comment /></metabolite><metabolite><id>579</id><name>N-Acetylaspartic acid</name><specimen>urine</specimen><value>increased</value><min>6.00</min><max>15.00</max><unit>mmol/mol creatinine</unit><age>childhood 6-12y</age><method /><comment /></metabolite><metabolite><id>580</id><name>N-Acetylaspartic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>11.00</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method /><comment /></metabolite><metabolite><id>980</id><name>N-Acetylaspartic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>92.00</max><unit>mmol/mol creatinine</unit><age>infancy</age><method /><comment /></metabolite><metabolite><id>1545</id><name>N-Acetylaspartic acid</name><specimen>urine</specimen><value>increased</value><min>6.00</min><max>36.00</max><unit>mmol/mol creatinine</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>979</id><name>N-Acetylaspartic acid</name><specimen>cerebrospinal fluid</specimen><value>increased</value><min>0.25</min><max>2.83</max><unit>&#956;mol/l</unit><age>1 week - 14 years</age><method /><comment /></metabolite><metabolite><id>981</id><name>N-Acetylaspartic acid</name><specimen>plasma</specimen><value>increased</value><min>0.17</min><max>0.81</max><unit>&#956;mol/l</unit><age>ALL</age><method>GCMS</method><comment /></metabolite><metabolite><id>982</id><name>N-Acetylaspartic acid</name><specimen>amniotic fluid</specimen><value>increased</value><min>0.30</min><max>2.55</max><unit>&#181;mol/l</unit><age>adult</age><method /><comment /></metabolite><metabolite><id>541</id><name>Succinic acid</name><specimen>urine</specimen><value>increased</value><min>6.00</min><max>343.00</max><unit>mmol/mol creatinine</unit><age>infancy</age><method /><comment /></metabolite><metabolite><id>542</id><name>Succinic acid</name><specimen>urine</specimen><value>increased</value><min>4.00</min><max>27.00</max><unit>mmol/mol creatinine</unit><age>childhood 6-12y</age><method /><comment /></metabolite><metabolite><id>109</id><name>Succinic acid</name><specimen>urine</specimen><value>increased</value><min>5.30</min><max>46.30</max><unit>mmol/mol creatinine</unit><age>child</age><method /><comment /></metabolite><metabolite><id>356</id><name>Succinic acid</name><specimen>plasma</specimen><value>increased</value><min>0.00</min><max>32.00</max><unit>&#181;mol/l</unit><age>child</age><method /><comment /></metabolite><metabolite><id>357</id><name>Succinic acid</name><specimen>cerebrospinal fluid</specimen><value>increased</value><min>0.00</min><max>5.00</max><unit>&#956;mol/l</unit><age>child</age><method /><comment /></metabolite><metabolite><id>540</id><name>Succinic acid</name><specimen>urine</specimen><value>increased</value><min>29.40</min><max>486.20</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1488</id><name>Succinic acid</name><specimen>urine</specimen><value>increased</value><min>20.00</min><max>272.00</max><unit>mmol/mol creatinine</unit><age>newborn 1-7d</age><method /><comment /></metabolite><metabolite><id>1521</id><name>Succinic acid</name><specimen>urine</specimen><value>increased</value><min>40.00</min><max>125.00</max><unit>mmol/mol creatinine</unit><age>infancy</age><method /><comment /></metabolite><metabolite><id>1522</id><name>Succinic acid</name><specimen>urine</specimen><value>increased</value><min>5.00</min><max>81.00</max><unit>mmol/mol creatinine</unit><age>childhood</age><method /><comment /></metabolite><metabolite><id>1539</id><name>Succinic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>50.00</max><unit>mmol/mol creatinine</unit><age>ALL</age><method /><comment /></metabolite><metabolite><id>1688</id><name>Succinic acid</name><specimen>urine</specimen><value>increased</value><min>0.30</min><max>33.30</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite></Metabolites><Literatures><literature><id>6079</id><title>Canavan Disease</title><author>Bokhari MR1,</author><journal>StatPearls [Internet]</journal><year>2020</year><book /><volume>0</volume><number>0</number><pages /><co_aut>Bokhari SRA</co_aut></literature><literature><id>7628</id><title>Antisense Oligonucleotide Reverses Leukodystrophy in Canavan Disease Mice</title><author>Hull V,</author><journal>Ann Neurol</journal><year>2020</year><book /><volume>87</volume><number>3</number><pages>480-485</pages><co_aut>et al.</co_aut></literature><literature><id>7629</id><title>A case of juvenile Canavan disease with distinct pons involvement</title><author>Cakar NE,</author><journal>Brain Dev</journal><year>2020</year><book /><volume>42</volume><number>2</number><pages>222-225</pages><co_aut>Aksu Uzunhan T</co_aut></literature><literature><id>7003</id><title>Development of bisubstrate analog inhibitors of aspartate N-acetyltransferase, a critical brain enzyme</title><author>Mutthamsetty V,</author><journal>Chem Biol Drug Des</journal><year>2019</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>6077</id><title>Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy</title><author>von Jonquieres G,</author><journal>Acta Neuropathol</journal><year>2018</year><book /><volume>135</volume><number>1</number><pages>95-113</pages><co_aut>et al.</co_aut></literature><literature><id>6078</id><title>White matter disease: Targeted aspartoacylase gene therapy reverts Canavan disease</title><author>Starling S</author><journal>Nat Rev Neurol</journal><year>2018</year><book /><volume>14</volume><number>1</number><pages>4</pages><co_aut /></literature><literature><id>6824</id><title>Canavan Disease</title><author>Matalon R,</author><journal>GeneReviews&#174; [Internet]</journal><year>2018</year><book /><volume>0</volume><number>0</number><pages /><co_aut>Delgado L, Michals-Matalon K</co_aut></literature><literature><id>6080</id><title>Design and optimization of aspartate N-acetyltransferase inhibitors for the potential treatment of Canavan disease</title><author>Thangavelu B,</author><journal>Bioorg Med Chem</journal><year>2017</year><book /><volume>25</volume><number>3</number><pages>870-885</pages><co_aut>et al.</co_aut></literature><literature><id>8015</id><title>Increasing N-acetylaspartate in the Brain during Postnatal Myelination Does Not Cause the CNS Pathologies of Canavan Disease</title><author>Appu AP,</author><journal>Front Mol Neurosci</journal><year>2017</year><book /><volume>10</volume><number>0</number><pages>161</pages><co_aut>et al.</co_aut></literature><literature><id>6081</id><title>A case of Canavan disease with microcephaly</title><author>Gowda VK,</author><journal>Brain Dev</journal><year>2016</year><book /><volume>38</volume><number>8</number><pages>759-762</pages><co_aut>et al.</co_aut></literature><literature><id>6091</id><title>Cytotoxic edema and diffusion restriction as an early pathoradiologic marker in canavan disease: case report and review of the literature</title><author>Merrill ST,</author><journal>Orphanet J Rare Dis</journal><year>2016</year><book /><volume>11</volume><number>1</number><pages>169</pages><co_aut>et al.</co_aut></literature><literature><id>3343</id><title>Purification and characterization of aspartate N-acetyltransferase: A critical enzyme in brain metabolism</title><author>Wang Q,</author><journal>Protein Expr Purif</journal><year>2015</year><book /><volume>119</volume><number>0</number><pages>11-18</pages><co_aut>et al.</co_aut></literature><literature><id>3344</id><title>An atypical case of Canavan disease with stroke-like presentation</title><author>Delaney KE,</author><journal>Pediatr Neurol</journal><year>2015</year><book /><volume>52</volume><number>2</number><pages>218-221</pages><co_aut>et al.</co_aut></literature><literature><id>3345</id><title>Brain ultrasound in Canavan disease</title><author>Drera B,</author><journal>J Ultrasound</journal><year>2014</year><book /><volume>17</volume><number>3</number><pages>215-217</pages><co_aut>Poggiani C</co_aut></literature><literature><id>3346</id><title>Canavan disease: clinical features and recent advances in research</title><author>Hoshino H,</author><journal>Pediatr Int</journal><year>2014</year><book /><volume>56</volume><number>4</number><pages>477-483</pages><co_aut>Kubota M</co_aut></literature><literature><id>3347</id><title>A new mouse model of Canavan leukodystrophy displays hearing impairment due to central nervous system dysmyelination</title><author>Carpinelli MR,</author><journal>Dis Model Mech</journal><year>2014</year><book /><volume>7</volume><number>6</number><pages>649-657</pages><co_aut>et al.</co_aut></literature><literature><id>3348</id><title>Leukodystrophies with astrocytic dysfunction</title><author>Rodriguez D</author><journal>Handb Clin Neurol</journal><year>2013</year><book /><volume>113</volume><number>0</number><pages>1619-1628</pages><co_aut /></literature><literature><id>3349</id><title>A thematic review of scientific and family interests in Canavan Disease: where are the developmentalists?</title><author>Glicksman S,</author><journal>J Intellect Disabil Res</journal><year>2013</year><book /><volume>57</volume><number>9</number><pages>815-825</pages><co_aut>et al.</co_aut></literature><literature><id>3350</id><title>Leukodystrophies</title><author>Perlman SJ,</author><journal>Adv Exp Med Biol</journal><year>2012</year><book /><volume>724</volume><number>0</number><pages>154-171</pages><co_aut>Mar S</co_aut></literature><literature><id>2943</id><title>Glyceryl triacetate for Canavan disease: A low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor</title><author>Madhavarao CN</author><journal>J Inherit Metab Dis</journal><year>2009</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>2944</id><title>Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in canavan disea</title><author>Baslow MH</author><journal>Neurochem Res</journal><year>2009</year><book /><volume>34</volume><number>9</number><pages>1523-1524</pages><co_aut>Guilfoyle DN</co_aut></literature><literature><id>2945</id><title>Mutational analysis of aspartoacylase: implications for Canavan disease</title><author>Hershfield JR</author><journal>Brain Res</journal><year>2007</year><book /><volume>1148</volume><number>0</number><pages>1-14</pages><co_aut>et al.</co_aut></literature><literature><id>2946</id><title>N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology</title><author>Moffett JR</author><journal>Prog Neurobiol</journal><year>2007</year><book /><volume>81</volume><number>2</number><pages>89-131</pages><co_aut>et al.</co_aut></literature><literature><id>2658</id><title>Aspartoacylase is a regulated nuclear-cytoplasmic enzyme</title><author>Hershfield JR</author><journal>FASEB J</journal><year>2006</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>2659</id><title>Canavan disease: a white matter disorder</title><author>Kumar S</author><journal>Ment Retard Dev Disabil Res Rev</journal><year>2006</year><book /><volume>12</volume><number>2</number><pages>157-165</pages><co_aut>et al.</co_aut></literature><literature><id>2660</id><title>Mild-onset presentation of Canavans disease associated with novel G212A point mutation in aspartoacylase gene</title><author>Janson CG</author><journal>Ann Neurol</journal><year>2006</year><book /><volume>59</volume><number>2</number><pages>428-431</pages><co_aut>et al.</co_aut></literature><literature><id>2664</id><title>Canavan disease and the role of N-acetylaspartate in myelin synthesis</title><author>Namboodiri AM</author><journal>Mol Cell Endocrinol</journal><year>2006</year><book /><volume>252</volume><number>0</number><pages>216-223</pages><co_aut>et al.</co_aut></literature><literature><id>2661</id><title>Atypical MRI findings in Canavan disease: a patient with a mild course</title><author>Yalcinkaya C</author><journal>Neuropediatrics</journal><year>2005</year><book /><volume>36</volume><number>5</number><pages>336-339</pages><co_aut>et al.</co_aut></literature><literature><id>2662</id><title>Lithium citrate for Canavan disease</title><author>Janson CG</author><journal>Pediatr Neurol</journal><year>2005</year><book /><volume>33</volume><number>4</number><pages>235-243</pages><co_aut>et al.</co_aut></literature><literature><id>2663</id><title>Possible genotype-phenotype correlations in children with mild clinical course of Canavan disease</title><author>Tacke U</author><journal>Neuropediatrics</journal><year>2005</year><book /><volume>36</volume><number>4</number><pages>252-255</pages><co_aut>et al.</co_aut></literature><literature><id>2665</id><title>Dietary treatment proposed for Canavans disease</title><author>Chen V</author><journal>Lancet Neurol</journal><year>2005</year><book /><volume>4</volume><number>5</number><pages>273</pages><co_aut /></literature><literature><id>1688</id><title>Rapid and sensitive screening for and chemical diagnosis of Canavan disease by gas chromatography-mass spectrometry</title><author>Inoue Y</author><journal>J Chromatogr B Analyt Technol Biomed Life Sci</journal><year>2004</year><book /><volume>806</volume><number>1</number><pages>33-39</pages><co_aut>Kuhara T</co_aut></literature><literature><id>1689</id><title>Effect of topiramate on enlargement of head in Canavan disease: a new option for treatment of megalencephaly</title><author>Topcu M</author><journal>Turk J Pediatr</journal><year>2004</year><book /><volume>46</volume><number>1</number><pages>67-71</pages><co_aut>et al.</co_aut></literature><literature><id>1690</id><title>Mental retardation and hypotonia seen in the knock out mouse for Canavan disease is not due to succinate semialdehyde dehydroge</title><author>Surendran S</author><journal>Neurosci Lett</journal><year>2004</year><book /><volume>358</volume><number>1</number><pages>29-32</pages><co_aut>et al.</co_aut></literature><literature><id>1691</id><title>Canavan disease: carrier-frequency determination in the Ashkenazi Jewish population and development of a novel molecular diagno</title><author>Feigenbaum A</author><journal>Am J Med Genet</journal><year>2004</year><book /><volume>124</volume><number>2</number><pages>142-147</pages><co_aut>et al.</co_aut></literature><literature><id>1255</id><title>Canavans leukodystrophy is associated with defects in cochlear neurodevelopment and deafness</title><author>Ishiyama G</author><journal>Neurology</journal><year>2003</year><book /><volume>60</volume><number>10</number><pages>1702-1704</pages><co_aut>et al.</co_aut></literature><literature><id>1692</id><title>Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease: a mechanistic explanation</title><author>Baslow MH</author><journal>J Mol Neurosci</journal><year>2003</year><book /><volume>21</volume><number>3</number><pages>185-190</pages><co_aut /></literature><literature><id>1693</id><title>Metabolic changes in the knockout mouse for Canavans disease: implications for patients with Canavans disease</title><author>Surendran S</author><journal>J Child Neurol</journal><year>2003</year><book /><volume>18</volume><number>9</number><pages>611-615</pages><co_aut>et al.</co_aut></literature><literature><id>894</id><title>The clinical course of Canavan disease</title><author>Traeger EC</author><journal>Pediatr Neurol</journal><year>1998</year><book /><volume>18</volume><number>0</number><pages>207-212</pages><co_aut>Rapin I</co_aut></literature><literature><id>690</id><title>Disorders of neurotransmitter metabolism</title><author>Hyland K</author><journal>Physicians guide to the laboratory diagnosis of metabolic diseases; Chapman &amp; Hall, London</journal><year>1996</year><book /><volume>0</volume><number>0</number><pages>79-98</pages><co_aut>et al.</co_aut></literature><literature><id>821</id><title>Megencephaly: a new mouse mutation on chromosome 6 that causes hypertrophy of the brain</title><author>Danahue LR</author><journal>Mamm Genome</journal><year>1996</year><book /><volume>7</volume><number>0</number><pages>871-876</pages><co_aut>et al.</co_aut></literature><literature><id>180</id><title>Canavan disease: from spongy degeneration to molecular analysis</title><author>Matalon R</author><journal>J Pediatr</journal><year>1995</year><book /><volume>127</volume><number>0</number><pages>511-517</pages><co_aut>Michals K, Kaul R</co_aut></literature><literature><id>328</id><title>Aspartoacylase deficiency (Canavan disease)</title><author>Beaudet AL</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>3</volume><number>0</number><pages>4599-4605</pages><co_aut /></literature><literature><id>5947</id><title>Standardized method for high-resolution 1H-NMR of cerebrospinal fluid</title><author>Wevers RA,</author><journal>Clin Chem</journal><year>1995</year><book /><volume>41</volume><number>5</number><pages>744</pages><co_aut>et al.</co_aut></literature><literature><id>333</id><title>Canavan disease: genomic organisation and localisation of human ASPA to 17p13-ter and conservation of the ASPA gene during evolu</title><author>Kaul R</author><journal>Genomics</journal><year>1994</year><book /><volume>21</volume><number>2</number><pages>364-370</pages><co_aut>et al.</co_aut></literature><literature><id>330</id><title>Canavan disease: biochemical and molecular studies</title><author>Matalon R</author><journal>J Inherit Metab Dis</journal><year>1993</year><book /><volume>16</volume><number>0</number><pages>744-752</pages><co_aut>Kaul R, Michals K</co_aut></literature><literature><id>329</id><title>Stable isotope dilution analysis of N-Acetylaspartic acid in CSF, blood, urine and amniotic fluid: accurate postnatal diagnosis </title><author>Jakobs C</author><journal>J Inherit Metab Dis</journal><year>1991</year><book /><volume>14</volume><number>0</number><pages>653-660</pages><co_aut>et al.</co_aut></literature><literature><id>3184</id><title>Handbook of 1H-NMR spectroscopy in inborn errors of metabolism: body fluid NMR spectroscopy and in vivo MR spectroscopy</title><author>Engelke UFH</author><journal>SPS</journal><year>0</year><book /><volume>0</volume><number>0</number><pages /><co_aut>Wevers RA</co_aut></literature><literature><id>3185</id><title>Physicians Guide to the Laboratory Diagnosis of Metabolic Diseases</title><author>Blau N</author><journal>Springer</journal><year>0</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature></Literatures></Disease>